Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Study on the Safety and Efficacy of Umbilical Cord Blood Derived MAK Immune Cells Combined With Standard Second-Line Treatments for Hepatobiliary and Pancreatic Malignancies：HCCSC AB04 Trial

NCT05240690 is registered in ClinicalTrials.gov with Zhou Fuxiang as lead sponsor.

NCT NCT05240690
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05240690 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Study on the Safety and Efficacy of Umbilical Cord Blood Derived MAK Immune Cells Combined With Standard Second-Line Treatments for Hepatobiliary and Pancreatic Malignancies：HCCSC AB04 Trial
Lead sponsor
Zhou Fuxiang
Phase
Phase 1
Overall status
Unknown status
Start date
February 7, 2022
Completion date
December 31, 2024
Enrollment
27 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma , cholangiocarcinoma, stage iv pancreatic cancer